Who
Aoife Brennan
President and CEO
Company insider
Files Form 4 as: President and CEO, Climb Bio; Director, Xilio Therapeutics; Director, Kyntra Bio; President and CEO, Synlogic; Director, Ra Pharmaceuticals.
In numbers
- Trades disclosed
- 67
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $953K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 14 Mar 2018
- Last trade
- 29 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 30 Jun 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $407K30,902 at $13.17 | filing |
| 29 Jun 2026filed 30 Jun 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $407K30,902 at $13.17 | filing |
| 27 Jun 2026filed 30 Jun 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —68,750 | filing |
| 27 Jun 2026filed 30 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —68,750 at $0.00 | filing |
| 27 Jun 2026filed 30 Jun 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —68,750 at $0.00 | filing |
| 27 Jun 2026filed 30 Jun 2026 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —68,750 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 11 Jun 2026filed 12 Jun 2026 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 6 Jan 2026filed 8 Jan 2026 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 30 Jun 2025filed 1 Jul 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Sold | $25K20,618 at $1.22 | filing |
| 27 Jun 2025filed 1 Jul 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code M | —68,750 at $0.00 | filing |
| 27 Jun 2025filed 1 Jul 2025 | CLYM Climb BioBiotechnology | SEC FORM 4 Code M | —68,750 | filing |
| 11 Jun 2025filed 12 Jun 2025 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,000 at $0.00 | filing |
| 13 Jan 2025filed 15 Jan 2025 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —1,150,000 at $0.00 | filing |
| 27 Jun 2024filed 27 Jun 2024 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —550,000 at $0.00 | filing |
| 27 Jun 2024filed 27 Jun 2024 | CLYM Climb Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —275,000 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | XLO Xilio Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 5 Jun 2024filed 6 Jun 2024 | KYNB Kyntra Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 10 Nov 2023filed 14 Nov 2023 | Synlogicoption or derivative · Biotechnology | SEC FORM 4 Code D | —5,591 | filing |
News
No headline names them, or the companies they trade most, lately.